Shanda Begins Downsizing, Future Performance Uncertain
This article was originally published in PharmAsia News
Executive Summary
Shanda, plagued by debt, underperforming assets, and litigation since listing nine years ago, plans to sell 90 percent of its shares in Kangnuo Pharmaceutical